VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 16, 2025 | $1,140,000 | Replaced |
| 2nd Quarter - Amendment | Oct 9, 2025 | $1,140,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Medicare/Medicaid MMM
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Taxation/Internal Revenue Code TAX
Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility; Issues related to the One Big Beautiful Bill Act (PL 119-21).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SWARNA VALLURUPALLI | — |
Budget/Appropriations BUD
Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| KRISTIN RICHTER | — |
| MATTHEW O SCHUMAKER | — |
| SWARNA VALLURUPALLI | — |
Trade (domestic/foreign) TRD
Intellectual property reforms to address unfair trade practices in Argentina and Russia.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW O SCHUMAKER | — |
Pharmacy PHA
Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HANNAH BETH CORNWELL | — |
| KRISTIN RICHTER | — |
| SWARNA VALLURUPALLI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.